Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABAGART: abatacept versus placebo in giant cell arteritis
2024-515287-31-00Phase 3Authorised
- Sponsor
- University of Pennsylvania
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Abatacept with Placebo (2 arms). Primary endpoint: Remission at Month 12. Planned start Aug 2026; status: authorised.
02
Drugs
abatacept
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2024-515287-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515287-31-00.